Immunotherapy of Non-Small Cell Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 20 September 2025 | Viewed by 2965
Special Issue Editor
Special Issue Information
Dear Colleagues,
Antibody Drug Conjugates (ADCs) are the newer classes of immunotherapy drugs which present a promising but challenging therapeutic approach for Non-small cell lung cancer (NSCLC). They have shown promise in treating patients who have developed resistance to other therapies. Several ADCs are in clinical trial, targeting various antigens including TROP2, HER2 etc. Despite the promise, ADCs face significant challenges in NSCLC treatment including toxicity like interstitial lung disease (ILD), limited efficacy, identifying suitable surface targets and resistance. There is insufficient knowledge about how ADC targets are expressed in the body. A more thorough analysis of this expression could lead to a better understanding of adverse events, such as ILD. This improved understanding may help reduce the occurrence of these adverse effects. Our study aims to analyze the ADC target expression in lung tissue to help us understand the relation between ADCs and interstitial lung disease.
We look forward to receiving your contributions.
Dr. Aakash P. Desai
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- antibody drug conjugates
- ADCs
- non-small cell lung cancer
- NSCLC
- interstitial lung disease
- ILD
- TROP2
- ERBB2
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
